Embecta Corp.
EMBCHealthcareNASDAQMedical Instruments & Supplies · Last scanned Sep 8, 2026
Scan Results
Daily timeframeEmbecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. With a market capitalization of $328.6M, it sits in small-cap territory. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Market Cap
$328.6M
Beta
0.85
P/E (TTM)
3.95
P/E (Fwd)
3.29
EPS (TTM)
$1.47
EPS (Fwd)
$1.76
ROE
—
ROA
12.2%
Cash
$214.7M
Total Debt
$1.50B
Free CF
$138.2M
52W Change
-61.9%
Annual Financials
Cash vs Debt
Where EMBC stands vs its 150-day and 200-day moving averages
As of the August 31, 2026 close, EMBC finished 20.35% below its 150-day moving average ($6.34) and 35.34% below its 200-day moving average ($7.81). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is EMBC overbought or oversold?
At the August 31, 2026 close, EMBC's RSI(14) was 52.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, EMBC has $214.7M in cash with $1.50B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $138.2M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on assets of 12.2% further supports the picture of efficient asset utilization. Revenue has been relatively flat, moving from $1.13B (2022) to $1.08B (2025).
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. No single metric tells the full story. Reviewing EMBC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.